Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1643 1645
This examiner grants 44% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 16629264 | METHODS FOR DIAGNOSING PANCREATIC CANCER | Non-Final OA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH |
| 15768853 | POLYMERASE Q AS A TARGET IN HR-DEFICIENT CANCERS | Non-Final OA | DANA-FARBER CANCER INSTITUTE, INC. |
| 18359562 | INTERNALIZING RECEPTOR-DIRECTED BISPECIFIC BINDING AGENT-LIGAND FUSIONS FOR THE DEGRADATION OF TARGET PROTEINS | Non-Final OA | The Regents of the University of California |
| 18041059 | COMPANION DIAGNOSTIC FOR RTK INHIBITORS | Non-Final OA | The Regents of The University of Michigan |
| 18041527 | sBCMA Variants and FC Fusion Proteins Thereof | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17916942 | VACCINE PLATFORM FOR THE INDUCTION OF SYSTEMIC IMMUNE RESPONSES | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17416227 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Final Rejection | Board of Regents, The University of Texas System |
| 18247144 | INTEGRATED PROTEOMIC BIOMARKERS FOR THE DETECTION OF AGGRESSIVE PROSTATE CANCER | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 17797676 | CANCER IMMUNOTHERAPY USING TRANSFUSIONS OF ALLOGENEIC, TUMOR-SPECIFIC CD4+ T CELLS | Final Rejection | The Johns Hopkins University |
| 17101028 | METHODS AND ASSAYS RELATING TO CIRCULATING TUMOR CELLS | Final Rejection | THE GENERAL HOSPITAL CORPORATION |
| 17630046 | DOSAGE AND ADMINISTRATION REGIMEN FOR THE TREATMENT OR PREVENTION OF C5-RELATED DISEASES BY THE USE OF THE ANTI-C5 ANTIBODY CROVALIMAB | Final Rejection | HOFFMANN-LA ROCHE INC. |
| 17630050 | DOSAGE AND ADMINISTRATION REGIMEN FOR THE TREATMENT OR PREVENTION OF C5-RELATED DISEASES BY THE USE OF THE ANTI-C5 ANTIBODY CROVALIMAB | Final Rejection | HOFFMANN-LA ROCHE INC. |
| 18299415 | METHOD OF TREATING CANCER WITH A BRCA1-ASSOCIATED PROTEIN 1 INHIBITOR AND A DEATH RECEPTOR LIGAND | Final Rejection | UCL Business PLC |
| 17803392 | Fusion Protein Composition(S) Comprising Masked Type I Interferons (IFNa and IFNß) For Use in the Treatment of Cancer and Methods Thereof | Non-Final OA | Nammi Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy